Sep 14, 2021 17:46 JST

Source: Eisai

Eisai to Join The Global Environmental Initiative "RE100"

TOKYO, Sep 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity.

RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy with the aim of realizing a carbon-free society, and about 300 companies have joined worldwide. The Climate Group, an international environmental NGO, operates RE100 in partnership with CDP.

In May 2021, Eisai declared that it would achieve carbon neutrality in 2040 as a long-term goal for greenhouse gas (GHG) reduction. In addition, Eisai aims to increase the renewable energy usage rate of electricity throughout the Eisai Group to 100% by 2030 as its medium-term goal. With the accession to RE100, Eisai will accelerate its efforts to achieve the goals, promoting the use of solar power generation based on the PPA (Power Purchase Agreement) model and installing power generation equipment using natural energy in addition to the promotion of energy conservation and renewable energy utilization that has been carried out in Eisai. 

Regarding Eisai's accession to RE100, Sam Kimmins, Head of RE100 at Climate Group said: "We are delighted that Eisai has joined RE100 the global initiative led by the Climate Group in partnership with CDP. By committing to 100% renewable electricity by 2030, Eisai is taking leadership in climate action. They join more than 50 Japanese RE100 companies who collectively, send a powerful message that renewable electricity makes good business sense."

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. To realize this hhc philosophy, Eisai will further strengthen its activities to ensure the sustainability of the global environment, which is the basis of its business activities.

For more detailed information about Eisai's environmental activities, please visit
https://www.eisai.com/sustainability/environment/index.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Environment, ESG, BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
 
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
 
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
 
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
 
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
 
More Press release >>

Latest Press Release


More Latest Release >>